Although there is some evidence of the presence of activated ERK1/2 in NSCLC primary cancer cells derived from tumours as compared to normal lung cells (Hoshino et al, 1999), the extent of this activation and its meaning and role in patients with NSCLC remain to be defined. This evidence concerns the gene MAPK3 and neoplasm.